Nineteen health organisations and doctors' groups have written to Andy Burnham urging him to scrap the UK-US medicines trade deal. The letter, coordinated by the SOS NHS coalition and published by The Guardian on July 7, carries particular weight because Burnham is expected to become Labour leader and prime minister within weeks.

The deal was announced by the UK government on December 1, 2025, as part of the broader UK-US Economic Prosperity Deal, with its full legal text agreed by April 2, 2026, according to Reuters. On the surface, it looks like a commercial win: zero tariffs on UK pharmaceutical exports to the US for three years, a provision the Association of the British Pharmaceutical Industry welcomed as a boost to UK life sciences competitiveness.

The controversial part concerns how the NHS prices new medicines. Under the agreement, NICE's cost-effectiveness threshold — the ceiling per quality-adjusted life year (QALY) that determines whether the NHS will fund a new drug — rose from £20,000–£30,000 to £25,000–£35,000, an increase of 17% to 25%. A higher ceiling means the NHS will pay more for new medicines before deciding they're too expensive to cover.

Critics argue this shift effectively imports elements of US drug pricing — where medicines cost substantially more — into a system historically built on tighter cost control. The concern is compounded by changes to the statutory rebate scheme. Before the deal, pharmaceutical companies selling to the NHS faced a rebate rate of 23% under the UK's statutory pricing mechanism. Analysis cited in the SOS NHS letter estimates that £44.7 billion in NHS cash will be diverted from health services by 2036 to cover the cost of new medicines under the deal, unless the Treasury provides additional funding.

Academics from the University of York, the University of Liverpool, and Christchurch hospital in New Zealand have attached a human cost to that diversion. They project 229,000 excess deaths by 2036 if NHS spending is squeezed as their model suggests. The Guardian first reported this figure on July 1 and has since used it as the organising statistic around which the SOS NHS coalition's campaign is built.

Legal challenge has been building alongside the political campaign. The New Statesman reported in May that campaigners were preparing legal action against the government over the deal, framing it as a threat to the foundational principles of NHS provision. The current letter is signed by both clinical figures — such as Dr Tony O'Sullivan, co-chair of Keep Our NHS Public and a retired consultant paediatrician — and patient advocates like Hope Worsdale of Just Treatment, giving it standing across multiple stakeholder groups rather than appearing as purely activist pressure.

The letter's scope extends well beyond drug pricing. Signatories want Burnham to revisit PFI arrangements underpinning new neighbourhood health centres, reverse recent NHS job cuts, halt the expansion of private providers across NHS-commissioned services, and reconsider Palantir's NHS data contract. Bundling these demands signals that SOS NHS is treating the drug deal less as an isolated trade dispute and more as one thread in a wider argument about the steady shift toward private providers and outsourcing within the health service — a concern that predates this agreement but has found sharper focus through it.

Here's the political reality that matters. Burnham built much of his political identity on NHS advocacy, dating back to his time as health secretary. Campaigners are gambling that a leadership transition creates a rare window to reopen an agreement that Starmer's government has already signed and publicly defended. Whether a new prime minister would actually unwind a bilateral trade commitment with the United States — one bound up in a broader Economic Prosperity Deal — is a separate question from whether he sympathises with the underlying critique. The technical challenge is substantial: renegotiating or scrapping just the pharmaceutical elements without touching the tariff provisions the industry values would require the kind of surgical unpicking that no UK government has publicly attempted.

The Commons Library briefing situates the pharmaceutical agreement squarely within that larger Economic Prosperity Deal structure, a framing that matters for anyone judging how easily one component could be extracted. Trade tariffs and pricing thresholds are bundled together — and that structural coupling is likely to be the real terrain on which any future renegotiation is fought, regardless of who occupies Downing Street.